• T MacNeil, S Feighner, D L Hreniuk, J F Hess, and L H Van der Ploeg.
• Department of Genetics and Molecular Biology, Merck Research Laboratories, Rahway, NJ 07065, USA.
• Can. J. Physiol. Pharmacol. 1997 Jun 1;75(6):735-40.

AbstractWe developed a functional assay to evaluate the activity of kinin peptides at the human and mouse bradykinin (BK) B1 receptors. The photoprotein aequorin expressed in 293-AEQ17 cells was used to measure calcium mobilization due to activation of the human or mouse B1 receptors by kinin peptides. The B1 agonists des-Arg9-BK and des-Arg10-kallidin activated the human receptor (EC50 = 112 and 5 nM, respectively), whereas the B1 peptide antagonists des-Arg9,Leu8-BK and des-Arg10,Leu9-kallidin showed no activation. At the murine receptor, the agonists des-Arg9-BK and des-Arg10-kallidin activated the receptor with EC50 values of 39 and 23 nM, respectively. In contrast, the two peptide antagonists showed significant agonism at the murine receptor. Thirty-nine and 44% agonism of the mouse receptor was observed with des-Arg9,Leu8-BK (EC50 = 56 nM) and des-Arg10,Leu9-kallidin (EC50 = 177 nM). Two recently described kinin analogues, [Lys-Lys0,Hyp3,Igl5,D-Igl7,Oic8,des-Arg9]B K and [D-Arg0,Hyp3,Igl5,D-Igl7, Oic8,des-Arg9]BK (B9858 and des-Arg9-B9430), failed to agonize the mouse receptor. These peptides were potent antagonists of des-Arg10-kallidin- and des-Arg9-BK-induced bioluminescence at the cloned human and mouse B1 receptors.

21 keywords...

hide…